Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J5HU
|
|||
| Former ID |
DIB002090
|
|||
| Drug Name |
Ro-46-2005
|
|||
| Synonyms |
150725-87-4; Ro 46-2005; Ro-46-2005; RO462005; CHEMBL115951; ro46-2005; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl]benzenesulfonamide; Benzenesulfonamide,4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]-; 4-tert-butyl-N-{6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl}benzenesulfonamide; ZNXOKLWCOWOECF-UHFFFAOYSA-N; AC1L3TVG; ACMC-20n61p; SCHEMBL2678965; KS-00001DFD; CTK4C6747; DTXSID80164598; ZINC1535471; BCP17756; BDBM50105015; AKOS030526571; Ro 462005
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Terminated | [1] | |
| Company |
Roche Holding AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27N3O6S
|
|||
| Canonical SMILES |
CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC=N2)OCCO)OC3=CC=CC(=C3)OC
|
|||
| InChI |
1S/C23H27N3O6S/c1-23(2,3)16-8-10-19(11-9-16)33(28,29)26-21-20(22(25-15-24-21)31-13-12-27)32-18-7-5-6-17(14-18)30-4/h5-11,14-15,27H,12-13H2,1-4H3,(H,24,25,26)
|
|||
| InChIKey |
ZNXOKLWCOWOECF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 150725-87-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endothelin receptor (EDNR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003082) | |||
| REF 2 | In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. 1993 Nov 15;334(2):210-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.